North America Conjugate Vaccine Market (2018-2023)

June 2018 | 75 pages | ID: N4CB1076A6CEN
Netscribes (India) Pvt. Ltd.

Abstracts

The report is sent in 5-10 business days after order is placed.

North America Conjugate Vaccine Market:

Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%.

Scheduled conjugated vaccinations, have eradicated health disparities and consequently led to lower rate of disease incidence.

Market Segmentation:

• Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics in North America was in the case of DTP vaccines.
• Based on end user, the market is segmented into pediatric and adult.
• Based on countries, the market is divided into U.S. and Canada.

Key growth factors:

North America is projected to be one of the most significant markets for conjugate vaccines during the forecast period, due to a rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Increased diagnosis and treatment are considered to fuel the North American conjugate vaccine market. Recommended vaccines and dosages are updated on a regular basis to comply with prevalent serogroups of infectious agents. For example, the CDC has its own immunization schedule for US citizens. This has increased the effectiveness of administered vaccines, which thereby increases the demand for the product, leading to increase in market sales.

Threats and key players:

• The North America conjugate vaccine market is expected to grow positively. But since it is a saturated market, the scope for significant growth is limited. In North America, the population above 65 years of age has decreased from 53,000,000 in 2014 to 51,900,000 in 2016. So, the demand for adult vaccines has also reduced. The overall penetration rate for the adult segment is lower than that of the pediatric segment.
• Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

What’s covered in the report?

1. Overview of the North America conjugate vaccine market
2. Market drivers and challenges in the North America conjugate vaccine market
3. Market trends in the North America conjugate vaccine market
4. Historical, current and forecasted market size data for North America based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for North America based on end user (pediatric and adult conjugate vaccines) – by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines by countries (U.S., Canada) – by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments – by revenue and by volume
8. Analysis of the competitive landscape and profiles of major companies operating in the North American market

Why buy?

• Understand the demand for conjugate vaccines to determine the viability of the market
• Understand the country-specific market size and observations for each segment
• Develop strategies based on the drivers, trends and highlights for each of the segments
• Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
• Recognize the key competitors of this market and respond accordingly
• Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
• Define the competitive positioning by comparing the products and services with the key players in the market

Customizations available

With the given market data, Netscribes offers customizations according to specific needs.

Contents

CHAPTER 1: EXECUTIVE SUMMARY

1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary  I
1.4 Executive summary  II

CHAPTER 2: MARKET OVERVIEW

2.1. Market definitions
2.2. North America market overview – by revenue
  North America historical (2015-2017) market revenue (USD Bn)
  North America forecasted (2018-2023) market revenue (USD Bn)
  Country-wise market (2018-2023) revenue (USD Bn)
2.3. North America market overview – by volume
  North America historical (2015-2017) market volume (Million units)
  North America forecasted (2018-2023) market volume (Million units)
  Country-wise (2018-2023) market volume (Million units)
2.4. North America market drivers and challenges
  2.4.1. North America market drivers
  2.4.2. North America market challenges
2.5. North America market trends
2.6. Value chain
  2.7.1. Country-specific market overview – U.S.
  Observation
  Key competitors
  2.7.1(A) Country-specific market overview – U.S. by revenue and by volume
  U.S. historical (2015-2017) market revenue (USD Bn)
  U.S. forecasted (2018-2023) market revenue (USD Bn)
  U.S. historical (2015-2017) market volume (Million units)
  U.S. forecasted (2018-2023) market volume (Million units)
  2.7.2. Country-specific market overview – Canada
  Observation
  Key competitors
  2.7.2(A) Country-specific market overview – Canada by revenue and by volume
  Canada historical (2015-2017) market revenue (USD Bn)
  Canada forecasted (2018-2023) market revenue (USD Bn)
  Canada historical (2015-2017) market volume (Million units)
  Canada forecasted (2018-2023) market volume (Million units)

CHAPTER 3: NORTH AMERICA MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION

3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): Pneumococcal – North America (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Hib – North America (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): DTP – North America (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Meningococcal – North America (USD Bn, Million units)

CHAPTER 4: NORTH AMERICA MAJOR SEGMENT OVERVIEW BY END USER

4.1. End user: Pediatric, Adult by revenue, by volume, CAGR
  Overview by end user
  Market share (2015, 2018 & 2023): Paediatric – North America (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Adult – North America (USD Bn, Million units)

CHAPTER 5: U.S. – BY DISEASE INDICATION

5.1. U.S.: disease indication  Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. U.S.: disease indication  Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. U.S.: disease indication  Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. U.S.: disease indication  Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

CHAPTER 6: U.S. – BY END USER

6.1. U.S.: end user  Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways

CHAPTER 7: CANADA – BY DISEASE INDICATION

7.1. Canada: disease indication  Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Canada: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Canada: disease indication  Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Canada: disease indication  Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

CHAPTER 8: CANADA – BY END USER

8.1. Canada: end user  Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Company market share
  Top 5 companies
9.2. Company overview GlaxoSmithKline
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.2(A) Executive profile – GlaxoSmithKline
9.3. Company overview – Pfizer Inc.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.3(A) Executive profile  Pfizer Inc.
9.4. Company overview – Merck & Co.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.4(A) Executive profile  Merck & Co.
9.5. Company overview – Novartis
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.5(A) Executive profile  Novartis
9.6. Company overview – Sanofi Pasteur
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.6(A) Executive profile  Sanofi Pasteur
9.7. Company overview – CSL Limited
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.7(A) Executive profile  CSL Limited
9.8. Company overview – Nuron Biotech Inc.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
9.8(A) Executive profile – Nuron Biotech Inc.
Appendix
  List of tables
  Assumptions
  Conclusion
  Research methodology
  About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research